|
1
|
Moch H, Montironi R, Lopez-Beltran A,
Cheng L and Mischo A: Oncotargets in different renal cancer
subtypes. Curr Drug Targets. 16:125–135. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Mijuskovic M, Stanojevic I, Milovic N,
Cerovic S, Petrovic D, Maksic D, Kovacevic B, Andjelic T, Aleksic
P, Terzic B, et al: Tissue and urinary KIM-1 relate to tumor
characteristics in patients with clear renal cell carcinoma. Int
Urol Nephrol. 50:63–70. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Manickam P, Kaushik A, Karunakaran C and
Bhansali S: Recent advances in cytochrome c biosensing
technologies. Biosens Bioelectron. 87:654–668. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Renz A, Berdel WE, Kreuter M, Belka C,
Schulze-Osthoff K and Los M: Rapid extracellular release of
cytochrome c is specific for apoptosis and marks cell death in
vivo. Blood. 98:1542–1548. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Wen Q, Zhang X, Cai J and Yang PH: A novel
strategy for real-time and in situ detection of cytochrome c and
caspase-9 in Hela cells during apoptosis. Analyst. 139:2499–2506.
2014. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Barczyk K, Kreuter M, Pryjma J, Booy EP,
Maddika S, Ghavami S, Berdel WE, Roth J and Los M: Serum cytochrome
c indicates in vivo apoptosis and can serve as a prognostic marker
during cancer therapy. Int J Cancer. 116:167–173. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Osaka A, Hasegawa H, Tsuruda K, Inokuchi
N, Yanagihara K, Yamada Y, Aoyama M, Sawada T and Kamihira S: Serum
cytochrome c to indicate the extent of ongoing tumor cell death.
Int J Lab Hematol. 31:307–314. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Medeiros LJ, Jones EC, Aizawa S, Aldape
HC, Cheville JC, Goldstein NS, Lubensky IA, Ro J, Shanks J, Pacelli
A and Jung SH: Grading of renal cell carcinom a: Workgroup No. 2.
union internationale contre le cancer and the American Joint
Committee on cancer (AJCC). Cancer. Sep. 80:990–991. 1997.
|
|
9
|
Lenburg ME, Liou LS, Gerry NP, Frampton
GM, Cohen HT and Christman MF: Previously unidentified changes in
renal cell carcinoma gene expression identified by parametric
analysis of microarray data. BMC Cancer. 3:312003. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Camp RL, Dolled-Filhart M and Rimm DL:
X-tile: A new bio-informatics tool for biomarker assessment and
outcome-based cut-point optimization. Clin Cancer Res.
10:7252–7259. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Kao SJ, Lee WJ, Chang JH, Chow JM, Chung
CL, Hung WY and Chien MH: Suppression of reactive oxygen
species-mediated ERK and JNK activation sensitizes
dihydromyricetin-induced mitochondrial apoptosis in human non-small
cell lung cancer. Environ Toxicol. 32:1426–1438. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Irizarry Rovira AR, Bennet BM, Bolon B,
Braendli-Baiocco A, Chandra S, Fleurance R, Garman R, Hutto D, Lane
J, Romeike A, et al: Scientific and regulatory policy committee
points to consider: Histopathologic evaluation in safety assessment
studies for PEGylated pharmaceutical products. Toxicol Pathol.
46:616–635. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Trotta AP and Chipuk JE: Mitochondrial
dynamics as regulators of cancer biology. Cell Mol Life Sci.
74:1999–2017. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Kadam CY and Abhang SA: Serum levels of
soluble Fas ligand, granzyme B and cytochrome c during adjuvant
chemotherapy of breast cancer. Clin Chim Acta. 438:98–102. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Vladimirov YA, Sarisozen C, Vladimirov GK,
Filipczak N, Polimova AM and Torchilin VP: The cytotoxic action of
cytochrome C/Cardiolipin nanocomplex (Cyt-CL) on cancer cells in
culture. Pharm Res. 34:1264–1275. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Hockenbery D, Nunez G, Milliman C,
Schreiber RD and Korsmeyer SJ: Bcl-2 is an inner mitochondrial
membrane protein that blocks programmed cell death. Nature.
348:334–336. 1990. View
Article : Google Scholar : PubMed/NCBI
|
|
17
|
Javid J1, Mir R, Julka PK, Ray PC and
Saxena A: Extracellular cytochrome c as a biomarker for monitoring
therapeutic efficacy and prognosis of non-small cell lung cancer
patients. Tumour Biol. 36:4253–4260. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Chen Q, Weng HY, Tang XP, Lin Y, Yuan Y,
Li Q, Tang Z, Wu HB, Yang S, Li Y, et al: ARL4C stabilized by
AKT/mTOR pathway promotes the invasion of PTEN-deficient primary
human glioblastoma. J Pathol. 247:266–278. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Loo JF, Lau PM, Kong SK and Ho HP: An
assay using localized surface plasmon resonance and gold nanorods
functionalized with aptamers to sense the cytochrome-c released
from apoptotic cancer cells for anti-cancer drug effect
determination. micromachines (Basel). 8(pii): E3382017. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Kim ST, Lee YJ, Hwang YS and Lee S: Study
on aggregation behavior of Cytochrome C-conjugated silver
nanoparticles using asymmetrical flow field-flow fractionation.
Talanta. 132:939–944. 2015. View Article : Google Scholar : PubMed/NCBI
|
